Christoph B. Olivier, Annabel Hölzle/LinkedIn
Mar 13, 2026, 22:05
Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”Congratulations Annabel for an outstanding presentation at the Spring School 2026!
Today Annabel Hölzle shared critical findings from her study: ‘Periprocedural hemostatic and inflammatory changes after TAVR and their association with hypoattenuating leaflet thickening (HALT).’
Her research provides vital clues to improve long-term patient safety in heart valve interventions.
We are very proud to see our team members leading such high-impact clinical discussions.
Great job, Annabel!”
Stay updated with Hemostasis Today.
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome
-
Apr 29, 2026, 16:12Mavis Agnes Kisakye: Concluding a Successful Entrepreneurs Training for Empowering Ptients’ Mothers
-
Apr 29, 2026, 15:48Kriti Batni: Happy to Share Current Use and Future Directions of Monoclonal Antibodies in Medicine Update 2026
-
Apr 29, 2026, 15:46Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
-
Apr 29, 2026, 15:44Sonal Sonu: Securing First Prize in Research Oral Presentation at the CME